Here are 1-3 brief analogies for Globus Medical (GMED):

• Like Stryker or Zimmer Biomet for spine, joint, and trauma surgical implants.
• The Medtronic of orthopedic and spine surgical solutions.
• Johnson & Johnson, but exclusively focused on musculoskeletal medical devices.

• Spine Products: A range of traditional fusion implants including pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating various spinal conditions.
• Motion Preservation Technologies: Devices such as dynamic stabilization, total disc replacement, and interspinous distraction devices designed to maintain spinal motion.
• Interventional Pain Management Solutions: Products developed to treat vertebral compression fractures.
• Regenerative Biologic Products: Allografts and synthetic alternatives used to promote healing and regeneration.
• Orthopedic Trauma Products: Solutions including fracture plates, compression screws, intramedullary nails, and external fixation systems for treating fractures and orthopedic injuries.
• Hip and Knee Joint Solutions: Implants such as modular hip stems, acetabular cups, and various knee arthroplasty implants for joint replacement.
• Human Cell, Tissue, and Cellular and Tissue-based Products: Distributed human cell, tissue, and cellular and tissue-based products.

Major Customers of Globus Medical (GMED)

Globus Medical, Inc. (GMED) primarily sells its medical devices and solutions to healthcare institutions rather than directly to individual patients. Due to the fragmented nature of the medical device industry, Globus Medical typically does not have a single major customer that accounts for a significant portion of its revenue, nor does it typically disclose specific customer names. Instead, its customer base comprises a broad network of:

• Hospitals: These are the primary institutions where surgical procedures utilizing Globus Medical's spine, trauma, and joint replacement products are performed.
• Ambulatory Surgical Centers (ASCs): Outpatient facilities that perform various surgical procedures, including those requiring Globus Medical's devices.
• Group Purchasing Organizations (GPOs): While not direct end-users, GPOs act as intermediaries, negotiating purchasing contracts on behalf of hospitals and other healthcare providers, thereby influencing where these institutions procure their medical supplies.

Keith Pfeil, President and Chief Executive Officer

Keith Pfeil has served as President and Chief Executive Officer of Globus Medical since July 2025. He joined Globus as Chief Financial Officer in August 2019, and in 2024, he was named Executive Vice President, Chief Operating Officer, and Chief Financial Officer. Prior to joining Globus, Mr. Pfeil spent approximately 16 years at CSS Industries, Inc., a publicly traded consumer products company, where he most recently served as Executive Vice President and Chief Financial Officer.

Kyle Kline, Senior Vice President and Chief Financial Officer

Kyle Kline has served as Senior Vice President and Chief Financial Officer since July 2025. He joined Globus Medical in May 2017 as Assistant Controller and has held roles of increasing responsibility in accounting and finance, including Senior Vice President of Finance, where he led the company's day-to-day accounting, finance, treasury, and tax functions.

David C. Paul, Executive Chairman

David C. Paul is the founder of Globus Medical, having established the company in 2003. He served as Chief Executive Officer from inception until August 2017, when he transitioned to the role of Executive Chairman. Prior to founding Globus, Mr. Paul was employed at Synthes, where his last position was Director of Product Development, responsible for product development and marketing functions. He is named inventor on over 300 patents and published applications.

Kelly G. Huller, Esquire, General Counsel

Kelly Huller has served as General Counsel since December 2018. She began her career at Globus in 2006 as the company's first in-house counsel. During her tenure, Ms. Huller has led more than 10 mergers and acquisitions, including the company's acquisition of NuVasive, Inc.

Brian Kearns, Senior Vice President, Business Development and Investor Relations

Brian Kearns has served as Senior Vice President of Business Development and Investor Relations for Globus Medical since January 2015. In this role, he is responsible for sourcing, evaluating, negotiating, and integrating all mergers and acquisitions, as well as investor relations and corporate communications. Before joining Globus, Mr. Kearns founded Kearns Consulting LLC in 2009, a consulting company that provided corporate development and strategic planning services to small to mid-sized healthcare companies. His prior experience also includes serving as CFO of a publicly traded generic pharmaceutical company and a publicly traded healthcare services company, as well as holding equity research positions at Salomon Smith Barney (now Citi) and Bank of America, and financial management roles at Johnson & Johnson. An SEC complaint related to his time as CFO of MedQuist was settled in 2009.

Here are the key risks to Globus Medical's business:

1. Integration Risks from the NuVasive Acquisition: Globus Medical's 2023 merger with NuVasive presents significant integration challenges that could disrupt operations and hinder expected synergies. These challenges include difficulties in consolidating manufacturing, rationalizing stock-keeping units (SKUs), harmonizing ERP systems, and aligning salesforces, which can defer anticipated benefits and distract commercial teams. The company experienced supply chain disruptions in Q1 2025 due to the active integration phase, which may have impacted order fulfillment and led to increased competitive pressure. Furthermore, there is a risk of sales representative attrition due to uncertainty about roles within the combined entity. Successful integration is crucial for achieving planned cross-selling opportunities, cost efficiencies, and margin expansion.
2. Regulatory Challenges and Compliance Issues: The medical device industry is subject to stringent regulatory requirements, and Globus Medical has recently faced compliance issues. The company received a warning letter from the U.S. Food and Drug Administration (FDA) in July 2024, following an inspection that identified deficiencies in product complaint procedures. These deficiencies included issues with complaint investigations, trending, risk reconciliation, and timely Medical Device Report (MDR) submissions, specifically pertaining to its ExcelsiusGPS® robotic system. This regulatory action led to a drop in the company's stock price and initiated an investigation into potential claims. Changes in regulations, both domestically and internationally, could also impose additional compliance costs or delay product launches.
3. Intense Competition and Pricing Pressures: Globus Medical operates in a highly competitive medical device market, particularly in spine, orthopedics, and trauma. The company faces continuous pressure to differentiate its products from those of larger rivals such as Medtronic, DePuy Synthes, Stryker, and Zimmer Biomet. These competitors invest heavily in implants, biologics, and enabling technologies, leading to aggressive pricing strategies and the risk of Globus Medical losing key contracts with hospitals and integrated delivery networks (IDNs). Hospitals are increasingly entering into preferred or exclusive contracts with large suppliers to control costs, which can limit surgeons' choices and exacerbate pricing pressures.

Globus Medical (NASDAQ: GMED) operates in several significant addressable markets related to musculoskeletal disorders, including spine products, orthopedic trauma, and hip and knee joint solutions.

Spine Products

The global spine market was valued at approximately $10.8 billion in 2024 and is projected to surpass $12.3 billion by 2028. Other estimates place the global spine market at $12.5 billion in 2024. The spinal implants and surgical devices market was estimated at $14.16 billion in 2024 and is expected to reach $24.50 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.63%. Another report values the spinal implants market at $15.14 billion in 2025, with a projection to reach $24.22 billion by 2033, expanding at a CAGR of 6.08% from 2026 to 2033. The spinal implants and surgical devices market is expected to grow from $13.57 billion in 2025 to $18.05 billion by 2031 at a 4.86% CAGR. The global spinal implants market was valued at $11.31 billion in 2024 and is expected to reach $19.08 billion by 2032, growing at a CAGR of 6.75% from 2025 to 2032. North America accounted for the largest share of the spinal implants market in 2025.

Orthopedic Trauma Products

The global orthopedic trauma devices market is estimated to reach $11.5 billion in 2025 and is predicted to rise to $17.5 billion by 2032, at a CAGR of 6.2%. Another source indicates the global orthopedic trauma device market was valued at $7.4 billion in 2024 and is expected to reach $8.9 billion by 2030, growing at a CAGR of 2.7%. The global orthopedic trauma devices market is projected to increase from $11,140.17 million in 2024 to $17,551.67 million by 2032, reflecting a CAGR of 5.89%. The orthopedic trauma device market is set to reach $12.2 billion in 2026, with a CAGR of 6.4% expected through 2036, totaling $22.6 billion. The global trauma implants market size is projected to be $8624.5 million in 2025 and is projected to reach $14273.51 million by 2033, with a CAGR of 6.50%. The global trauma fixation devices market size was $8.76 billion in 2024 and is projected to surpass $13.03 billion by 2034, with a CAGR of 4.05%. North America is projected to hold the largest share of the orthopedic trauma devices market in 2024, accounting for 41% of the global market.

Hip and Knee Joint Solutions

The global hip and knee replacement market size was $21,412.5 million in 2024, with expectations to expand at a CAGR of 6.00% between 2024 and 2031 to reach $32,196.48 million. Another estimate places the global artificial hip and knee joints market size at $12.57 billion in 2023, projected to grow at a CAGR of 2.85% from 2024 to 2030. The total hip and knee replacements market size was $22.9 billion in 2025 and is expected to grow to $24.05 billion in 2026 at a CAGR of 5.0%, and further to $30.23 billion in 2030 at a CAGR of 5.9%. The global orthopedic large joint device market was valued at over $20.5 billion in 2023 and is expected to reach over $25.7 billion, at a CAGR of 3.3%. The global joint replacement market size was $23.56 billion in 2025 and is predicted to increase to $35.01 billion by 2035, expanding at a CAGR of 4.04% from 2026 to 2035. The global joint replacement devices market is projected to reach $31.1 billion by 2030 from $23.4 billion in 2024, at a CAGR of 4.8%. The hip replacement market alone is expected to grow from $6.92 billion in 2024 to nearly $10.24 billion by 2033, at a CAGR of 4.45% from 2025 to 2033. North America was the largest region in the total hip and knee replacements market in 2025.

Globus Medical (GMED) is poised for future revenue growth over the next 2-3 years, driven by several strategic initiatives and strong performance in key business segments. The company's management and industry analysts have highlighted the following drivers:

1. Successful Integration of Acquisitions: The ongoing and successful integration of recent acquisitions, particularly NuVasive and Nevro, is expected to continue boosting Globus Medical's overall trajectory and contribute to its financial performance. The Nevro acquisition, in particular, has been noted for its profitability accretion ahead of schedule.
2. Continued Growth and Market Share Gains in the U.S. Spine Business: Globus Medical's U.S. Spine business has consistently demonstrated strong, above-market growth and significant market share gains. This momentum is anticipated to be durable and sustained, serving as a primary organic growth engine for the company.
3. Expansion of Enabling Technologies: The Enabling Technologies segment, which includes advanced surgical robotics and navigation systems such as ExcelsiusFlex and the Excelsius XR augmented reality headset, has shown robust performance. This segment is expected to continue its strong growth trajectory, driven by increased adoption and successful deal closures for these innovative systems.
4. Robust New Product Pipeline and Innovation: Globus Medical emphasizes a strong commitment to innovation, with a robust pipeline of new products across its musculoskeletal portfolio. Management plans to continue launching new products to address unmet clinical needs, contributing to ongoing profitable growth and market share expansion.
5. Sales Force Expansion and Enhanced Market Penetration: The company aims to drive growth by expanding its "high-touch sales force" and improving market penetration. This focus on commercial execution, coupled with ongoing investment in sales and marketing, is expected to increase the reach of Globus Medical's solutions both domestically and internationally.